Drugs & Targets Foundation Medicine & Natera provide early access to personalized circulating tumor DNA monitoring assay January 13, 2023Vol.49 No.02
Drugs & Targets Kronos Bio & Genentech to collaborate on therapies against transcriptional targets January 13, 2023Vol.49 No.02
Drugs & Targets FDA grants accelerated approval to Lunsumio for R/R follicular lymphoma January 06, 2023Vol.49 No.01
Drugs & Targets FDA approves first gene therapy for high-risk, non-muscle-invasive bladder cancer January 06, 2023Vol.49 No.01
Drugs & Targets FDA approves imaging drug to help identify lung cancer lesions January 06, 2023Vol.49 No.01
Drugs & Targets FDA accepts supplemental BLAs for Padcev + Keytruda for urothelial cancer January 06, 2023Vol.49 No.01
Drugs & Targets Panel submits operational evaluation of FDA’s tobacco program January 06, 2023Vol.49 No.01
Drugs & Targets EC approves allogeneic T-cell immunotherapy in rare cancer January 06, 2023Vol.49 No.01
Drugs & Targets Caris and Xencor expand collaboration for XmAb antibody drug candidates January 06, 2023Vol.49 No.01
